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Infections with human parvoviruses B19 and recently discovered human bocaviruses (HBoVs) are
widespread, while PARV4 infections are transmitted parenterally and prevalent specifically in injecting
drug users and hemophiliacs. To investigate the exposure and circulation of parvoviruses related to B19 virus,
PARV4, and HBoV in nonhuman primates, plasma samples collected from 73 Cameroonian wild-caught
chimpanzees and gorillas and 91 Old World monkey (OWM) species were screened for antibodies to recom-
binant B19 virus, PARV4, and HBoV VP2 antigens by enzyme-linked immunosorbent assay (ELISA). Moderate
to high frequencies of seroreactivity to PARV4 (63% and 18% in chimpanzees and gorillas, respectively), HBoV
(73% and 36%), and B19 virus (8% and 27%) were recorded for apes, while OWMs were uniformly negative (for
PARV4 and B19 virus) or infrequently reactive (3% for HBoV). For genetic characterization, plasma samples
and 54 fecal samples from chimpanzees and gorillas collected from Cameroonian forest floors were screened
by PCR with primers conserved within Erythrovirus, Bocavirus, and PARV4 genera. Two plasma samples
(chimpanzee and baboon) were positive for PARV4, while four fecal samples were positive for HBoV-like
viruses. The chimpanzee PARV4 variant showed 18% and 15% nucleotide sequence divergence in NS and
VP1/2, respectively, from human variants (9% and 7% amino acid, respectively), while the baboon variant was
substantially more divergent, mirroring host phylogeny. Ape HBoV variants showed complex sequence rela-
tionships with human viruses, comprising separate divergent homologues of HBoV1 and the recombinant
HBoV3 species in chimpanzees and a novel recombinant species in gorillas. This study provides the first
evidence for widespread circulation of parvoviruses in primates and enables future investigations of their
epidemiology, host specificity, and (co)evolutionary histories.
Autonomous parvoviruses known to infect humans comprise
parvovirus B19 (18) and the recently discovered PARV4 (22)
and human bocavirus (HBoV) (3). Members of the family
Parvoviridae are genetically and biologically diverse and are
classified into several genera or groups, showing marked dif-
ferences in host range, pathology, and tissue/cellular tropisms
(18). Human parvovirus B19, a member of the Erythrovirus
genus, is transmitted primarily by the respiratory route but
causes systemic infections. Erythroid progenitor cells are spe-
cifically targeted through expression of globoside P antigen,
which acts as the B19 virus receptor for entry (5). In common
with infections by most parvoviruses, B19 virus infections are
acute; a period of intense viremia is followed by seroconver-
sion for antibody to B19 virus and lifelong immunity from
reinfection (29). Despite the clearance of viremia and serocon-
version for antibody, lifelong persistence of viral DNA in tis-
sues has been shown to occur (12, 20, 26, 28, 43, 58). Three
genotypes of B19 virus have been described, differing in
nucleotide sequence by approximately 13 to 14% (7, 21, 41,
53); genotypes 1 and 2 have been found in Europe, the
United States, and other Western countries, while genotype
3 is restricted to sub-Saharan Africa and South America (7,
47, 49). B19 virus widely circulates in human populations
worldwide; in Western countries, several studies have doc-
umented increasing frequencies of B19 virus seropositivity
with age, rising to approximately 60 to 70% by adulthood
(15, 39, 48, 61).
Another human parvovirus, PARV4, shows markedly differ-
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ent epidemiology and transmission routes. It was originally
detected in plasma from an individual with an “acute infection
syndrome” resembling that of primary human immunodefi-
ciency virus (HIV) infection (22). While this clinical presenta-
tion has not been observed again, infection with PARV4 is
known to be widespread specifically in individuals with a his-
tory of parenteral exposure (injecting drug users [IDUs], he-
mophiliacs, polytransfused individuals), with a strikingly higher
incidence in those infected with HIV-1 (13, 14, 30, 35, 54).
These observations suggest that PARV4 is primarily transmit-
ted though parenteral routes in Western countries (54, 56). In
common with infection with the better-characterized human
parvovirus B19, infection with PARV4 is associated with a
period of acute viremia, followed by seroconversion for anti-
body and long-term persistence of viral DNA sequences in
lymphoid and other tissue (33, 37, 52). Circulating variants of
PARV4 have been classified into three distinct genotypes ex-
hibiting approximately 8% nucleotide sequence divergence
from each other. Genotypes 1 and 2 circulate in Western coun-
tries, while genotype 3 has to date been recorded only in
sub-Saharan Africa (45, 55).
The third human parvovirus, HBoV (3), shows a number of
epidemiological and clinical attributes different from those of
both B19 virus and PARV4. HBoV was originally found in the
respiratory tract of young children and has been the subject of
intense investigation as a potential cause of human respiratory
disease (reviewed in references 1, 51, and 62). Although it is
frequently detected by PCR in the nasopharynx of viremic
individuals with primary infections with lower respiratory tract
disease, other coinfecting respiratory viruses are frequently
detected (19). HBoV additionally shows long-term, low-level
carriage in the respiratory tract after primary infection, which
further complicates PCR-based etiological studies (2, 38) and
warrants the use of other diagnostic strategies, such as serology
(30, 32, 59). In contrast to the rather minimal genetic diversity
of B19 virus and PARV4 genotypes, bocaviruses infecting hu-
mans are now known to comprise three to four major genetic
variants (termed types or species 1 to 4) (23, 24). HBoV1 and
HBoV2 show 22%, 33%, and 20% amino acid sequence diver-
gence from each other in the encoded viral nonstructural (NS),
NP-1, and structural VP1/VP2 proteins, respectively, the latter
potentially leading to antigenic diversity and some loss of an-
tigenic cross-reactivity. A third type/species of HBoV is a chi-
meric form with a nonstructural gene region (NS, NP1) most
similar to HBoV1, a recombination breakpoint in the inter-
genic region between NP1 and VP1, and structural genes re-
lated to those of HBoV2 (4, 23). Current data suggest that only
HBoV1 is capable of infecting the respiratory tract; most pub-
lished large-scale screening studies have failed to detect
HBoV2 (or HBoV3) in respiratory samples (10, 11, 60), while
all three types/species are detectable in fecal samples, indicat-
ing the existence of an alternative or additional site of virus
replication (23). Despite extensive inquiry, the exact role of
HBoV1 in respiratory disease remains unclear, as is the pro-
posed etiological role of HBoV2 (and possibly HBoV3) in
gastroenteritis (4, 11, 23, 50). Very recently, a fourth species/
type, HBoV4, has been detected in fecal samples; genetically it
also shows evidence for past recombination, with NS and NP1
region sequences grouping with HBoV2, while VP1/VP2 is
more closely related to HBoV3 (23).
We have little understanding of the past epidemiology, evo-
lution, and origins of human parvoviruses. For both B19 virus
and PARV4, evidence has been obtained for a temporal suc-
cession of genotypes over time (37, 43); in Europe, B19 virus
genotype 1 largely replaced type 2 in the 1960 and 1970s (43),
while current data indicate that a similar replacement of
PARV4 genotypes occurred within the last 20 years (37). The
highly restricted sequence diversity of currently circulating
variants of PARV4 and B19 virus and of HBoV1 variants
supports the hypothesis of a relatively recent emergence and
spread of these viruses in human populations (36, 42, 64).
The existence and evolution of parvoviruses on a much
longer time scale is suggested by the observations that mem-
bers of the Erythrovirus and Parvovirus genera both contain
viruses that are highly host species specific and that the mo-
lecular phylogenies of both genera are largely congruent with
those of their hosts (34). This has led to the hypothesis of
long-term coevolution of parvoviruses with their host over the
90 million years of mammalian evolution and perhaps beyond.
Among erythroviruses, simian homologues of B19 virus have
been found in cynomolgus monkeys (44) and rhesus and pig-
tailed macaques (16) and more genetically distant viruses have
been characterized in chipmunks and cows (9, 63). Divergent
homologues of PARV4 in pigs and cows have been described
(31), while the bovine and canine parvoviruses distantly related
to HBoV are the originally described members of the Bocavi-
rus genus. However, the process of virus-host codivergence is
known to be punctuated by occasional cross-species transmis-
sions, including the well-documented spread of feline parvovi-
rus to dogs (46). Based on serological evidence, the possible
transmission of simian erythroviruses to animal handlers has
been proposed (6).
To gain further insights into the origins and evolution of
human parvoviruses, we have performed large-scale serologi-
cal and PCR-based screening of nonhuman primates (chim-
panzees and gorillas) and of several species of Old World
monkeys (OWMs) for evidence of infection with parvoviruses
that are antigenically related to the human B19, PARV4, and
HBoV viruses. By PCR, we have sought to genetically charac-
terize homologues of the three autonomous human parvovi-
ruses in apes and Old World monkey species and to analyze
their evolutionary relationship to human and other mamma-
lian homologues of these viruses.
MATERIALS AND METHODS
Samples. Plasma samples were collected from 62 chimpanzees (Pan troglodytes
troglodytes), 11 gorillas (Gorilla gorilla), and a range of Old World monkey
species: Cercocebus agilis (n  7), C. torquatus (n  2), C. cephus (n  3), C.
erythrotis (n  4), C. preussi (n  4), C. mona (n  9), C. nictitans (n  3), C.
pogonias (n  1), C. tantalus (n  3), Erythrocebus patas (n  3), Lophocebus
albigena (n  5), Mandrillus leucophaeus (n  20), M. sphinx (n  9), and Papio
anubis (n  20). Sample shipment to the United Kingdom from Cameroon was
performed in compliance with Convention on International Trade in Endan-
gered Species of Wild Fauna and Flora (CITES) regulations and Cameroon and
United Kingdom import/export regulations. Samples were collected from captive
animals in three wildlife sanctuaries. Animals were primarily wild born and
brought to the sanctuaries after confiscation by authorities or abandonment by
owners. Blood samples were collected during routine health examinations, quar-
antine, or recaptures by sanctuary staff after escapes. Whole blood was collected
via venipuncture and transferred to an EDTA Vacutainer. Plasma was separated
by centrifugation and frozen at80°C until testing. Fecal samples were obtained
from 27 chimpanzees and 27 gorillas from the Cameroon (40); species identifi-
10290 SHARP ET AL. J. VIROL.
cation was performed by mitochondrial DNA, microsatellite, and sex marker
analyses as described previously (25).
Screening by PCR. Prior to nucleic acid extraction, fecal samples of approxi-
mately 50 to 300 mg were supplemented with 50 l of sterile PBS and briefly
mixed by vortexing. Samples were then cleared by centrifugation at 6,000 rpm in
a benchtop microcentrifuge for 1 min to pellet bacteria and other solids. DNA
extractions were performed (from either cleared fecal supernatants or 50 l of
plasma) using the AllPrep DNA/RNA minikit (Qiagen) according to the man-
ufacturer’s instructions with DNA eluted in a final volume of 50 l.
Samples were screened by nested PCR using sets of primers conserved
within each parvovirus genus (see Table S1 at http://www.virus-evolution.org
/Downloads/JVI01304-10/). For detection of PARV4, primers matched all de-
scribed sequences of PARV4, porcine hokovirus (PHoV), and bovine hokovirus
(BHoV) sequences. Erythrovirus primers were conserved between B19 and ma-
caque erythroviruses. Bocavirus primers matched NS or VP1/2 coding regions of
all currently published types/species of human bocavirus. First-round reactions
were performed using the outer primer sets listed above, 5 l of extracted DNA
as a template, and GoTaq reagents (Promega) according to the manufacturer’s
instructions. Second-round reactions were performed with inner primer sets and
1 l of first-round product as a template. Cycling conditions for both rounds were
as follows: 30 cycles of 18 s at 94°C, 30 s at 50°C, and 90 s at 72°C and a final
extension of 6 min at 72°C.
Direct sequencing of PCR products and sequence analysis. Positive second-
round PCR amplicons were sequenced in both directions using the inner sense
and inner antisense primers used in the second round of amplification. Sequenc-
ing was carried out using BigDye Terminator v3.1 (Applied Biosystems) accord-
ing to the manufacturer’s instructions. Sequences were read at the Gene Pool
facility (University of Edinburgh) and analyzed using Simmonic Sequence Editor
v1.9 software.
Serology assays. B19 virus screening was performed by commercially available
enzyme-linked immunosorbent assay (ELISA) (Biotrin, Dublin, Ireland) accord-
ing to the manufacturer’s instructions. Wells were coated with recombinant B19
virus VP2 protein, and antibody binding was detected by peroxidase-labeled
rabbit antihuman IgG followed by substrate (2,2 azinobis 3-ethylbenthiazoline-
6-sulfonate) incubation. Samples were scored as positive according to the man-
ufacturer’s criteria based on calibrator control cutoff values.
PARV4 IgG detection was performed for each sample in replicate by indirect
ELISA using baculovirus-expressed VP2 and control antigens as previously de-
scribed (54). Due to a high background reactivity observed for some samples, an
additional stipulation that positive samples must demonstrate a VP2 reactivity to
a control reactivity optical density ratio of greater than 1.3 was used and any
potentially positive samples falling below this cutoff were excluded from analysis.
By this criterion, two samples from chimpanzees were omitted from the PARV4
seroprevalence totals.
HBoV1 VP2 recombinant proteins were expressed as previously described
(59). For HBoV2, VP2 sequences (GenBank accession no. ACJ38942 and
ACR15792) were synthesized and cloned in pUC57 by GenScript and transferred
to the baculovirus vector pAcSG2 (Becton Dickinson Biosciences, Franklin
Lakes, NJ) by standard cloning practices. Expression and purification of the
proteins were performed as previously described (32, 59). ELISA for HBoV
antibody was performed in parallel with wells coated with HBoV1 or HBoV2
antigens; reactivity to one or both antigens greater than two standard deviations
above the negative-control mean was scored as positive.
Nucleotide sequence accession numbers. All sequences have been submitted
to GenBank and have been assigned the GenBank numbers HQ113143 to
HQ113151.
RESULTS
Seroprevalence for B19 virus, PARV4, and HBoV antibod-
ies. Serological testing of primates used antibody assays previ-
ously developed for human samples. To determine whether
anti-human IgG conjugates were reactive with ape and OWM
IgG, direct ELISA of dilution series of representative plasma
samples from each species along with human plasma controls
was performed. Equivalent reactivity of the conjugates used in
B19 virus, PARV4, and HBoV serological assays for IgG of
human, ape, and OWMs was observed (see Fig. S1 at http:
//www.virus-evolution.org/Downloads/JVI01304-10/), indicat-
ing the applicability of the serology assays for primate screen-
ing purposes.
Plasma samples collected from 62 chimpanzees, 11 gorillas,
and 91 Old World monkey species were screened for antibody
to B19 virus, PARV4, and HBoV1/HBoV2 (Fig. 1). High fre-
quencies of serological reactivity to PARV4, B19 virus, and
HBoV were observed for chimpanzees (63%, 73%, and 8%,
respectively), lower frequencies were observed for gorillas
(18%, 36%, and 27%, respectively), and reactivity was absent
in OWMs. In the last group, single samples from a drill (M.
leucophaeus), a mona monkey (C. mona), and a Preuss’s mon-
key (C. preussi) were positive for HBoV antibodies.
Genetic characterization of nonhuman parvoviruses. The
high frequency of serological reactivity to PARV4 in samples
from chimpanzees and gorillas suggested the existence of vi-
ruses related to human PARV4 circulating in apes. To genet-
ically characterize these variants, plasma and fecal samples
from these species were screened for PARV4 DNA using
primers conserved between human variants and the PARV4-
like viruses described in pigs and cows (see Table S1 at http://www
.virus-evolution.org/Downloads/JVI01304-10/). From these, one
plasma sample from a (seropositive) chimpanzee (PT-P48) and
one from a (seronegative) baboon (Papio anubis; PA-P68)
were detectably viremic. Nested primers generated overlap-
ping fragments of PARV4 spanning the genome from the
chimpanzee sample, while the baboon sample was positive only
with the screening primers originally used.
The chimpanzee samples yielded a near-complete genomic
sequence of the chimpanzee PARV4 homologue, which was
compared to PARV4 variants infecting humans and with the
FIG. 1. Frequency of serological reactivity of chimpanzee, gorilla,
and OWP plasma samples in B19 virus, PARV4, and HBoV antibody
ELISAs (number positive/number tested shown above each bar).
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more distantly related porcine and bovine viruses (Fig. 2). In
both genes (NS and VP1/VP2), nucleotide sequences from the
chimpanzee variant were substantially more similar to those of
human viruses (mean 18.2% and 15.2% divergence in NS and
VP1/VP2 genes, respectively, to human genotypes 1 to 3) than
to porcine and bovine viruses (41.5% and 43.3% and 36.9%
and 37.8%, respectively, in the two regions). The chimpanzee
variant was, however, substantially more divergent from hu-
man viruses than the three genotypes were from each other
(mean intertype pairwise distances of 8.7% and 6.6% in NS
and VP1/VP2, respectively). All phylogenetic analyses place
the chimpanzee strain as a close outgroup to the human ge-
notypes, with strong bootstrap support (Fig. 2). Translated
sequences from the VP2 gene of the chimpanzee variant
showed 6.9% amino acid sequence divergence from human
variants, a level of diversity consistent with the evident cross-
reactivity observed by serological screening. Although only a
relatively short region could be amplified from the baboon
sample, comparison of the VP2 sequences revealed an in-
termediate phylogenetic position; the baboon strain was
more divergent from human sequences than the chimpanzee
variant but more similar than the porcine or bovine homo-
logues (Fig. 2C).
For analysis of HBoV-like viruses in apes and OWMs,
plasma and fecal samples were screened for HBoV DNA using
primers conserved between HBoV1 and HBoV2. HBoV se-
quences were detected in fecal samples from two chimpanzees
(PT-BQ2392 and PT-LM1861) and two gorillas (GG-CP1426
and GG-GB2154). Sequences could be amplified from the NS
gene (positions 1096 to 1581) for all four positive samples,
while three were amplifiable in VP2 (positions 4343 to 4828).
Comparison of these sequences with available (nonredundant)
complete genome sequences of HBoV1 to HBoV4 showed
phylogenetic relationships with human-derived viruses that
were more complex than those exhibited by the chimpanzee
homologues of human PARV4 (Fig. 3). The sequence hetero-
geneity among chimpanzee and gorilla HBoV variants was
considerable, at least matching that observed among human
viruses.
The chimpanzee variant BQ2392 was most similar to
HBoV1 in both NS and VP2 regions (9.6% and 13.0% nucle-
otide sequence divergence, substantially greater than observed
within human-derived HBoV1 sequences [0.2% and 1.7%]).
The degree of divergence between this chimpanzee variant and
HBoV1 was much less than between HBoV types/species (e.g.,
mean HBoV1-HBoV2 distances were 24.6% and 24.4%, re-
spectively). BQ2392 might therefore be provisionally regarded
as the chimpanzee homologue of HBoV1. The other chimpan-
FIG. 2. Phylogenetic analysis of (A) complete NS and (B) VP1/VP2 gene sequences and (C) partial VP2 sequence (positions 3067 to 3310) of
the chimpanzee and baboon variants (PT-P48 and PA-P68; solid circles) and available complete genome sequences of PARV4 genotypes (Gt) 1
to 3 and of porcine and bovine homologues (PHoV, BHoV). Different species and genotypes are represented with different symbols and shading.
PARV4 sequences showing 0.5% divergence from other sequences were excluded from analysis. The trees were constructed by neighbor joining
of pairwise Jukes-Cantor corrected distances between nucleotide sequences; bootstrap values of 70% are shown.
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zee-derived variant (LM1861) was genetically distinct. It also
fell within the HBoV1/HBoV3 clade in the NS region and was
indeed most similar to HBoV3 (human-derived) sequences
(9.0%). However, in the VP2 region, it showed an outgroup
relationship to HBoV2, HBoV3, and HBoV4 (15.4% to 16.2%
divergence), rather that retaining its clustering with HBoV3.
These inconsistent phylogenetic relationships provide evidence
for further recombination events in the evolution of HBoV
infecting apes.
Finally, the two gorilla-derived viruses were highly similar to
each other in the NS region but showed no clear grouping with
any single human (or chimpanzee) type species in either ge-
nome region. In NS, they were was most similar to HBoV1 and
HBoV3 (15.5% and 13.6% divergence, respectively), while in
the VP2 region analyzed its closest relative was HBoV1 (al-
though showing 16.2% sequence divergence). Using the crite-
ria that differentiate HBoV1-HBoV3, the gorilla-derived vi-
ruses would represent a further, equivalently different
bocavirus type or species.
Using B19 virus-specific primers conserved among primate
erythroviruses, all samples of plasma and feces from apes and
OWMs were PCR negative.
DISCUSSION
This study provides the first evidence for the existence and
widespread infection of nonhuman primates with parvoviruses
genetically and antigenically related to PARV4, HBoV, and
B19 virus. Our initial strategy of screening for anti-parvovirus
antibodies was dictated by the acute/resolving nature of infec-
tions and absence of persistent viremia or fecal shedding. Popu-
lation exposure in nonhuman primates was therefore estimated
through serological testing for antibodies to each virus rather than
screening samples by PCR to detect acute infections.
Serological screening methods. The effectiveness of serolog-
ical screening for estimating population or species exposure to
a virus is dependent on both the durability of IgG responses
after acute infection (i.e., whether the response is lifelong),
and the extent of antigenic cross-reactivity between the virus in
the target population and the protein used in ELISA. In the
current study, we were reassured in both of these aspects.
For B19 virus, it is well established that high-affinity IgG
reactivity to nondenatured VP2 antigen (such as that used in
the current study) has a lifelong persistence after the initial
infection (57). The continuing presence of B19 virus in a wide
variety of tissues and minor reactivations that restimulate the
immune system potentially contribute to this long-term sero-
positivity. PARV4 shows evidence for tissue persistence (33,
37, 52) and likely lifelong seropositivity after resolution of
acute infections. Although several studies have failed to doc-
ument an equivalent persistence of HBoV in lymphoid tissue,
bone marrow, or skin (27, 37, 43), high frequencies of serolog-
ical reactivity in human adults have been observed using a
VP2-based ELISA similar to that used in the current study (8,
17, 30). These indicate a likely durable immune response
and/or the occurrence of multiple infections that restimulate
humoral antibody responses (17, 38).
In terms of cross-reactivity of human and primate viruses,
the high PARV4 seroprevalence (63%) in chimpanzees pro-
vides evidence that extensive serological cross-reactivity with
FIG. 3. Phylogenetic analysis of partial NS (positions 1096 to 1581) and VP1/VP2 (positions 4343 to 4828) gene sequences of bocavirus-like
sequences amplified from chimpanzee (prefixed PT) and gorilla (GG) positive fecal samples. Sequences were compared with available complete
genome sequences of HBoV1-HBoV4 and the more divergent canine (MVC) and bovine (BPV-1) members of the Bocavirus genus. Different
species and genotypes are represented with different symbols and shading. HBoV1 and HBoV2 sequences showing 0.5% divergence from other
sequences were excluded from analysis. The trees were constructed by neighbor joining of pairwise Jukes-Cantor corrected distances between
nucleotide sequences; bootstrap values of 70% are shown.
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human PARV4 antigen does indeed occur. This supposition is
supported by the observation of a relatively low level of amino
acid sequence divergence between chimpanzee-derived and
human PARV4 VP2 proteins (Table 1). For bocaviruses, se-
quence divergence of 10% or less between chimpanzee-derived
and human viruses similarly predicts antibody cross-reactivity.
However, the variant detected in the two positive gorilla samples
showed no clear grouping with any of the four human types/
species and its greater divergence in the region of VP2 sequenced
(16.2%) may reduce cross-reactivity considerably. The 36% sero-
prevalence detected for gorillas (Fig. 1) may there represent an
underestimate of their true rate of exposure.
The B19 virus serology data contain some interpretation
difficulties, since our PCR-based screening of plasma and fecal
samples failed to detect ape or OWM homologues of B19 virus
that would have allowed us to characterize them genetically.
To date, the only nonhuman primate B19 viruses in the Eryth-
rovirus genus have been obtained from macaques (16, 44).
These show approximately 34% sequence divergence in VP2
from human B19 virus, a level of divergence that likely pre-
cludes cross-reactivity in the serology assay for OWM species
investigated in the current study. Indeed, the uniformly nega-
tive (PARV4, B19 virus) or low frequency of (3% for HBoV)
reactivity observed on screening OWMs in the current study
most likely arose because of serological non-cross-reactivity
rather than an absence of parvovirus homologues in these
species. For PARV4, this hypothesis is strengthened by the
finding by PCR of a virus variant in a baboon that was sero-
negative for anti-PARV4 antibodies. For future studies,
screening of tissues rather than plasma may provide a better
opportunity to detect and genetically characterize these vi-
ruses, since B19 virus and PARV4 can be found in the tissues
of nonviremic humans (37, 43).
Population exposure of nonhuman primates to parvovi-
ruses. Notwithstanding the caveats discussed in the previous
section concerning serological cross-reactivity, our seropreva-
lence results for apes represent a minimum estimate of popu-
lation exposure to homologues of B19 virus, PARV4, and
HBoV in wild ape populations. Based on these data, gorilla
and chimpanzee homologues of all three human parvoviruses
circulate extensively among wild ape populations, with partic-
ularly high rates of exposure to PARV4- and HBoV-like vi-
ruses in chimpanzees. While the seroprevalence for HBoV
matches that of human populations (8, 17), the observation of
63% seroprevalence for PARV4 in chimpanzees appears at
odds with that observed for human populations studied so far
(54). As described in the introduction, PARV4 has a very
specific risk group association with parenteral exposure in
Western countries, with high rates of exposure recorded only
in IDUs and those exposed to plasma products, such as hemo-
philiacs (13, 14, 35, 54). However, there is increasing evidence
for a different epidemiology and possible alternate transmis-
sion routes for human PARV4 in sub-Saharan Africa. A very
recent study has described high viremia frequencies in young
children in Ghana without a history of parenteral exposure
(45), while PARV4 infection has been detected in HIV-in-
fected African men from Central/West Africa without an ob-
vious past parenteral exposure (33, 55). We have additionally
recently performed a large-scale serological screen for PARV4
antibodies of over 900 hepatitis C virus (HCV)- and HIV-
uninfected blood donor/adult population samples collected
from several countries in sub-Saharan Africa. Seroprevalences
of PARV4 in HCV- and HIV-uninfected groups were 37% in
Burkina Faso, 35% in the Cameroon, 25% in the Democratic
Republic of Congo, and 8% in South Africa. This findings
contrast markedly with a zero seroprevalence (0 of 360 sam-
ples) in French blood donors and United Kingdom low-risk
controls (54a), and among 115 low-risk controls in Finland
(30). The transmission route(s) responsible for such high ex-
posure in Africa is currently undetermined, although it is most
unlikely to be parenteral (as it is in Western countries) and is
additionally not associated with HIV infection in Central Af-
rica. If there is an environmental source of infection, this may
also underlie the high rate of seropositivity in nonhuman pri-
mates. Longitudinal studies documenting when PARV4 infec-
tions occur in both humans and apes are required to better
characterize the sources and risk factors for this virus infection.
Given the seroprevalance of PARV4 in humans and nonhu-
man primates in sub-Sarahan Africa, it seems reasonable to
posit that PARV4 infections observed in IDUs most likely
originated from this region. However, the timescale and route
of PARV4 emergence in Western countries is not yet known.
TABLE 1. Sequence divergence of ape-derived parvoviruses to
human and animal homologues of PARV4 and HBoV
Ape virus and
parvovirus
homologue
% Sequence divergence
NS region VP1/VP2 region
Nucleotide Aminoacid Nucleotide
Amino
acid
PT-P48
(chimpanzee)
PARV4 Gt 1 18.6 8.6 15.1 6.8
Gt 2 17.9 8.2 15.3 7.0
Gt 3 18.0 9.2 15.3 7.0
BHoV 41.5 42.2 36.9 34.7
PhoV 43.3 42.8 37.8 36.4
BQ2392
(chimpanzee)
HBoV1 9.6 3.1 13.0 4.5
HBoV2 25.5 19.2 25.1 21.3
HBoV3 17.4 5.7 25.4 21.7
HBoV4 26.7 20.4 24.7 21.5
MVC 47.6 53.9 57.9 70.4
BPV-1 50.5 58.0 51.6 66.2
LM1861
(chimpanzee)
HBoV1 16.3 5.6 20.2 18.6
HBoV2 25.0 19.5 16.0 10.2
HBoV3 9.0 4.0 15.4 11.0
HBoV4 26.3 20.4 16.2 13.3
MVC 46.9 52.0 56.5 71.6
BPV-1 50.1 58.0 51.8 64.6
CP1426/GB2154
(gorilla)
HBoV1 15.5 4.2 17.3 16.2
HBoV2 23.7 19.6 24.8 20.8
HBoV3 13.6 3.8 22.8 22.9
HBoV4 25.4 20.4 23.4 22.8
MVC 46.7 51.4 57.7 71.5
BPV-1 50.8 57.3 49.7 66.6
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Genetic diversity and evolution of parvoviruses. The newly
characterized PARV4- and HBoV-like viruses recovered from
nonhuman primates showed a consistently closer evolutionary
relationship to human viruses than to homologues infecting
pigs and cows (PARV4) or to the host species of viruses that
formed the original Bocavirus genus (dogs, cows). It has been
suggested that the parvoviruses have coevolved and codiverged
with their mammalian hosts, implying that the common ances-
tor of this group of viruses is at least 90 million years old (34).
For example, the relationships among human B19 virus and
erythroviruses from three macaque species corresponded to rela-
tionships among their hosts as revealed by mitochondrial se-
quences (34). Although we have not been able to genetically
characterize ape homologues of B19 virus, the PARV4 and
HBoV-like viruses found in apes in the current study are substan-
tially more genetically similar to human variants than macaque
B19-like viruses are to human B19 virus. This lends further, al-
though indirect, support to the coevolution hypothesis.
On the other hand, specific instances of cross-species trans-
mission have been identified in the evolution of parvoviruses,
most obviously the recent transmission of feline parvovirus to
dogs (46). There are additionally murine and hamster parvo-
viruses showing mosaicism between genome regions (34), com-
parable to the chimeric nature of HBoV3 and HBoV4 (23).
Phylogenetic relationships of the ape-derived HBoV-like vi-
ruses were complex, with further examples of inconsistent phy-
logenetic relationships between NS and VP2 regions indicative
of recombination events in the evolutionary history of ape
bocaviruses. Further genetic characterization and a larger sam-
ple set will be required to accurately document the evolution-
ary process underlying the current diversity of HBoV variants
detected in apes. One intriguing interpretation of the data
obtained in the current study is that chimpanzee and gorilla-
associated viruses represent separate, divergent ape homo-
logues for HBoV1, HBoV2, and the recombinant HBoV3; the
phylogeny of these outliers indeed recapitulates sequence re-
lationships between chimpanzee and human PARV4 variants.
This would logically place the evolution of bocaviruses, includ-
ing the recombination event that created HBoV3, before ape
speciation 5 million years ago if we follow the coevolution
model. However, we acknowledge that much more extensive
characterization of parvovirus homologues in OWMs and
those in the New World is required as additional data points to
fully substantiate the hypothesis of parvovirus/primate coevo-
lution in the three parvovirus genera we have analyzed.
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